Practical handling of allergic reactions to COVID-19 vaccines
Open Access
- 19 April 2021
- journal article
- research article
- Published by Springer Nature in Allergo Journal International
- Vol. 30 (3) , 79-95
Abstract
Summary: Background: For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global research effort studied the safety and efficacy of new vaccine platforms that have not been previously used in humans. Less than one year after the discovery of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral sequence, these vaccines were approved for use in the European Union (EU) as well as in numerous other countries and mass vaccination efforts began. The so far in the EU approved mRNA vaccines BNT162b2 and mRNA-1273 are based on similar lipid-based nanoparticle carrier technologies; however, the lipid components differ. Severe allergic reactions and anaphylaxis after COVID-19 vaccination are very rare adverse events but have drawn attention due to potentially lethal outcomes and have triggered a high degree of uncertainty. Methods: Current knowledge on anaphylactic reactions to vaccines and specifically the new mRNA COVID-19 vaccines was compiled using a literature search in Medline, PubMed, as well as the national and international study and guideline registries, the Cochrane Library, and the Internet, with special reference to official websites of the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), Robert Koch Institute (RKI), and Paul Ehrlich Institute (PEI). Results: Based on the international literature and previous experience, recommendations for prophylaxis, diagnosis and therapy of these allergic reactions are given by a panel of experts. Conclusion: Allergy testing is not necessary for the vast majority of allergic patients prior to COVID-19 vaccination with currently licensed vaccines. In case of allergic/anaphylactic reactions after vaccination, allergy workup is recommended, as it is for a small potential risk population prior to the first vaccination. Evaluation and approval of diagnostic tests should be done for this purpose.Keywords
Funding Information
- Charité
This publication has 73 references indexed in Scilit:
- Usefulness of oral macrogol challenge in anaphylaxis after intra‐articular injection of corticosteroid preparationAllergy, 2008
- Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patientsAllergy, 2008
- Contact sensitivity to octyldodecanol and trometamol in an anti-itch creamContact Dermatitis, 2007
- Anaphylactic shock after oral intake and contact urticaria due to polyethylene glycolsAllergy, 2006
- Two cases of anaphylaxis to macrogol 6000 after ingestion of drug tabletsAllergy, 2006
- Hypersensitivity and Loss of Disease Site Targeting Caused by Antibody Responses to PEGylated LiposomesMolecular Therapy, 2006
- Anaphylaxis to macrogol 4000 after a parenteral corticoid injectionAllergy, 2005
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- Sensitization to thimerosal (Merthiolate) is still present todayContact Dermatitis, 1994
- Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivoBiochimica et Biophysica Acta (BBA) - Biomembranes, 1991